» Authors » Jeremy J Erasmus

Jeremy J Erasmus

Explore the profile of Jeremy J Erasmus including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 123
Citations 2510
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Erasmus J, Vlahos I
J Thorac Oncol . 2023 Apr; 18(5):556-558. PMID: 37087116
No abstract available.
2.
Mitchell K, Bayley E, Ikoma N, Antonoff M, Mehran R, Rajaram R, et al.
Ann Thorac Surg . 2023 Apr; 117(2):320-326. PMID: 37080372
Background: Whereas current guidelines recommend staging laparoscopy for most patients with potentially resectable gastric cancer, such a recommendation for patients with adenocarcinoma of the gastroesophageal junction (AEG) is lacking. This...
3.
Betancourt Cuellar S, Benveniste M, Truong M, Nguyen Q, Atiyah A, Hofstetter W, et al.
Am J Clin Oncol . 2022 Dec; 46(1):25-30. PMID: 36562692
Objective: To determine the incidence and various patterns of radiation-induced liver injury (RILI) and its temporal evolution on fluorodeoxiglucose-positron emission tomography/computed tomography (FDG-PET/CT) after neoadjuvant chemoradiation using precision radiation in...
4.
Betancourt-Cuellar S, Palacio D, Benveniste M, Mawlawi Y, Erasmus J
Semin Ultrasound CT MR . 2021 Dec; 42(6):535-541. PMID: 34895609
The management of patients with esophageal carcinoma (EC) requires accurate clinical staging and post-therapeutic evaluation. Currently, esophagogastroduodenoscopy/endoscopic ultrasound (EGD/EUS), endoscopic ultrasound-fine needle aspiration (EUS-FNA), computed tomography (CT), 18F- fluoro-2-deoxy-D-glucose positron...
5.
Feldman H, Erasmus J, Zhou N, Antonoff M, Mehran R, Rajaram R, et al.
Ann Thorac Surg . 2021 Oct; 114(4):1183-1188. PMID: 34634240
Background: The assumption that increased [F] fluoro-2-deoxy-d-glucose (FDG) uptake in hilar nodes on positron emission tomography/computed tomography (PET/CT) imaging is indicative of distant metastasis can result in palliative rather than...
6.
Skinner H, Hu C, Tsakiridis T, Santana-Davila R, Lu B, Erasmus J, et al.
JAMA Oncol . 2021 Jul; 7(9):1324-1332. PMID: 34323922
Importance: Non-small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin has significant data supporting its use as an antineoplastic agent. Objective: To compare chemoradiation alone vs chemoradiation and metformin...
7.
Patel R, He K, Barsoumian H, Chang J, Tang C, Verma V, et al.
Radiother Oncol . 2021 Jul; 162:60-67. PMID: 34237343
Aim: To report early findings from a phase II trial of high-dose radiotherapy (HD-RT) with or without low-dose RT (LD-RT) for metastatic cancer. Methods: Eligible patients had metastatic disease that...
8.
Lowenstein L, Godoy M, Erasmus J, Zirari Z, Bennett A, Leal V, et al.
JCO Oncol Pract . 2020 Mar; 16(8):e703-e725. PMID: 32208092
Purpose: The uptake of shared decision making (SDM) for lung cancer screening (LCS) as required by the Centers for Medicare & Medicaid Services (CMS) is suboptimal. Alternative models for delivering...
9.
Pasalic D, Betancourt-Cuellar S, Taku N, Ludmir E, Lu Y, Allen P, et al.
Head Neck . 2020 Mar; 42(8):1939-1953. PMID: 32129548
Background: Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two-year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Methods: Retrospective review...
10.
Pasalic D, Lu Y, Betancourt-Cuellar S, Taku N, Mesko S, Bagley A, et al.
Radiother Oncol . 2020 Feb; 145:178-185. PMID: 32044530
Background & Purpose: Stereotactic ablative radiation therapy (SABR) is an emerging treatment option for patients with pulmonary metastases; identifying patients who would benefit from SABR can improve outcomes. Materials &...